Why is the decentralization of clinical studies suddenly so popular? In addition to the necessity for remote solutions in keeping trials on track during COVID-19 protocols, CROs and sponsors alike are looking beyond the current pandemic and realizing the advantages of decentralized strategies through digital technology – ranging from remote monitoring and patient accessibility to data intelligence and eSourcing. So how do drug developers identify the best way to conduct clinical trials with decentralization solutions in neurology and CNS-related therapeutic areas?
In an upcoming webinar, two medical experts will be discussing the integration of decentralization strategies into upcoming and current neurology clinical trials. Our goal is for sponsors and other clinical trial stakeholders to understand that challenges and obstacles common to neurology clinical trials can be addressed by leveraging digital technology innovations.
This online decentralization event will focus on digitization and digital solutions for neurology studies inclusive of patient access, assessments, and project management and tracking. We will also touch upon digital therapeutics (DTx), evidence-based software programs designed to treat behavioral conditions and other areas that can be optimized through decentralization strategies.
Decentralization is growing to become a larger component of the neurology clinical trial landscape, and digital technology solutions are helping this evolution occur.
Jimmy El Hokayem, Ph.D., Associate Director of Program Development and Head of the Neurology and Regenerative Medicine Centers of Excellence, Biorasi
As head of Biorasi’s Neurology and Regenerative Medicine Centers of Excellence, Dr. El Hokayem oversees all clinical studies and projects related to these therapeutic indications, leveraging his long-standing expertise in basic, translational and clinical research at strategic, operational and managerial levels. Dr. El Hokayem is an expert clinical trial de-centralizer and an early adopter of digital technologies in clinical studies as well as digital therapeutics.Message Presenter
Sharief Taraman, M.D., DABPN, DABPM, FAAP, CMO, Cognoa
Dr. Sharief Taraman is the Chief Medical Officer at Cognoa, Inc., a Silicon Valley based start-up that develops artificial intelligence-based digital diagnostics and personalized therapeutics that provide accurate, earlier diagnoses and more effective treatments to improve outcomes and lower behavioral healthcare costs. Dr. Taraman is dual board-certified in neurology with special qualifications in child and in clinical informatics. He remains clinically active as the Division Chief of the CHOC Children’s Specialists Pediatric Neurology Division and a Health Sciences Associate Clinical Professor at UC Irvine School of Medicine. Dr. Taraman is active in the community as a board member of the AAP Orange County Chapter, Irvine Unified School District Medical Advisory Board.Message Presenter
Who Should Attend?
- Clinical Teams
- Research and Development Teams
- Digital Health Teams
- Clinical Trial Management Teams
- Outsourcing Managers
What You Will Learn
In this webinar, participants will learn about:
- Developing decentralized strategies for improving patient access
- Incorporating eSourcing and other digitization solutions
- Optimizing data intelligence for full clinical trial transparency and visibility
- Building potential for digital therapeutic solutions in cognitive behavioral therapy
- Understanding the importance of integrating digital technology to decentralize neurology clinical trials in the current COVID-19 landscape and beyond
Biorasi is a customer-focused, full-service, contract research organization (CRO) that optimizes the design and delivery of clinical trials for its sponsors, powered by our proprietary TALOS™ project management system. Biorasi is a leader in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market.
Established in 2002, Biorasi is headquartered in Aventura, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC.
Please connect with us on LinkedIn.
Cognoa is the leading digital therapeutics company developing FDA regulated products to be routinely prescribed by pediatricians and paid by insurers, to diagnose and treat behavioral health conditions, starting with autism. Cognoa is focused on changing the current standard of care to ensure children receive early intervention for behavioral health conditions for improved lifelong outcomes. Cognoa is currently working with the FDA as part of a clinical trial and expects to achieve FDA clearance by 2021.